DMPK Resources
Links to some of my industry publications and Regulatory guidance(s):
Approaches for Reducing Liability to Major Metabolically Driven Causes Of Drug Attrition: The Challenge To De-Risk Pharmaceuticals (Pharma Outsourcing)
De-Risking Drug Development (Medicine Maker)
The use of radiolabelled compounds in the investigation of Metabolism and Drug-Drug Interactions in vitro (PharmaChem, p2 onwards)
Drug Transporters: Emerging Technologies (PharmaChem, p13 onwards)
Useful Regulatory Guidance
Drug-Drug Interactions (DDI):
**New FDA DDI Draft Guidance, January 2020**
Current EMA (Europe) DDI Draft Guidance, July, 2012:
New PMDA (Japan) DDI Guidance - English Translation:
MIST:
**New FDA MIST Draft Guidance, March 2020**
EMA Guidance for Non-Clinical Studies to Enable Human Clinical Trials
IND/CTA guidance:
ICH Topic M 3 (R2) Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals
FDA Guidance for Non-Clinical Studies to Enable Human Clinical Trials